pcDNA3-AU1-mTOR-E2419K Citations (4)

Originally described in: Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells.
Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M, Tamanoi F Proc Natl Acad Sci U S A. 2007 Feb 27. 104(9):3514-9. PubMed Journal

---

Articles Citing pcDNA3-AU1-mTOR-E2419K

Articles
mTORC1-independent TFEB activation via Akt inhibition promotes cellular clearance in neurodegenerative storage diseases. Palmieri M, Pal R, Nelvagal HR, Lotfi P, Stinnett GR, Seymour ML, Chaudhury A, Bajaj L, Bondar VV, Bremner L, Saleem U, Tse DY, Sanagasetti D, Wu SM, Neilson JR, Pereira FA, Pautler RG, Rodney GG, Cooper JD, Sardiello M. Nat Commun. 2017 Feb 6;8:14338. doi: 10.1038/ncomms14338. PubMed
FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. Okada K, Nogami A, Ishida S, Akiyama H, Chen C, Umezawa Y, Miura O. Oncotarget. 2017 Dec 4;9(10):8870-8886. doi: 10.18632/oncotarget.22926. eCollection 2018 Feb 6. PubMed
Constitutive Activation Mutant mTOR Promote Cone Survival in Retinitis Pigmentosa Mice. Rajala A, Wang Y, Rajala RVS. Adv Exp Med Biol. 2018;1074:491-497. doi: 10.1007/978-3-319-75402-4_61. PubMed
GZ17-6.02 Interacts With [MEK1/2 and B-RAF Inhibitors] to Kill Melanoma Cells. Booth L, West C, Von Hoff D, Kirkwood JM, Dent P. Front Oncol. 2021 Apr 8;11:656453. doi: 10.3389/fonc.2021.656453. eCollection 2021. PubMed

If you have published an article using this material, please email us at to have your article added to this page.